COMMUNIQUÉS West-GlobeNewswire

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
01/10/2025
- Meeting date aligns with prior guidance - - FDA to review AEON’s analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: [...]
Solid Biosciences to Present at Upcoming Scientific Meetings
01/10/2025
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from [...]
ATMA CENA Grows National Mental Health Network to 13 Clinics
01/10/2025
Expanding access to safe, regulated psychedelic-assisted therapy across Canada CALGARY, Alberta, Oct. 01, 2025 (GLOBE NEWSWIRE) -- ATMA CENA, a Canadian mental health company specializing in psychedelic-assisted therapy [...]
Stryker to announce financial results for its third quarter of fiscal year 2025
01/10/2025
Portage, Michigan, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its third quarter of fiscal year 2025 on Thursday, October 30, 2025. A press release will be [...]
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
01/10/2025
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the protocol-planned dose of 40mCi SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics ( [...]
CorVista Health Appoints Guido Neels and Dino Trevisani to Board of Directors
01/10/2025
Veteran MedTech leader Guido Neels joins CorVista, leveraging his experience as EW Healthcare Partners Operating Partner and former Guidant COO. Company founder Dino Trevisani returns to CorVista, bringing decades of [...]
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
01/10/2025
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food [...]
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
01/10/2025
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
01/10/2025
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of [...]
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
01/10/2025
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that [...]
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
01/10/2025
Appointments expand clinical and regulatory capabilities ahead of key program milestones BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on the [...]
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
01/10/2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
01/10/2025
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, [...]
Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors
01/10/2025
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7 ORANGE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan , an award-winning [...]
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
01/10/2025
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug [...]
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
01/10/2025
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
01/10/2025
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% [...]
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
01/10/2025
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting in promising functional improvements in [...]
Primary.Health Launches Nation's First Advanced Newborn Screening Case Management Platform
01/10/2025
Primary’s cloud-based system modernizes state newborn screening tracking and follow-up, incorporating cutting-edge science, evidence-based clinical protocols, and emerging screening methodologies to ensure no baby falls [...]

Pages